RICHLAND, Wash., Aug. 31, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE
MKT: ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications for the
treatment of prostate, brain, lung, head and neck and gynecological
cancers, today announced it will be featured as a presenting
company at the 19th Annual Rodman & Renshaw Global
Investment Conference, sponsored by H.C.
Wainwright & Co., LLC. The conference is being
held on September 10-12, 2017 at
Lotte New York Palace Hotel in New York
City.
Tom LaVoy, CEO of IsoRay, will
provide an overview of the Company's business during the live
presentation and will be available to participate in one-on-one
meetings with investors who are registered to attend the
conference.
If you are an institutional investor, and would like to attend
the Company's presentation, please click on the following link
(www.rodmanevents.com) to register for the Rodman & Renshaw
conference. Once your registration is confirmed, you will be
prompted to log into the conference website to request a one-on-one
meeting with the Company.
Event: 19th
Annual Rodman & Renshaw Global Investment Conference
Date: September 11, 2017
Time: 12:05pm Eastern Time
Location: Adams; Lotte New York Palace Hotel in
New York City
The presentation will be webcast live. To access the
webcast, please visit www.rodmanevents.com. The webcast
replay will remain available for 90 days following the live
presentation.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is
the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more
about this innovative Richland,
Washington company and explore the many benefits and uses of
Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay.
Follow us on Twitter@IsoRay.
Safe Harbor Statement
Statements in this news release about IsoRay's future
expectations, including: our preliminary financial results for
fiscal 2017 and the fourth quarter of 2017, the positive industry
data fueling renewed interest in brachytherapy, strong patient
results, whether interest in and use of our products will increase
or continue, whether the changes to the sales staff will result in
increased sales, whether further automation of production processes
will be completed or will result in lower costs, whether revenue
will increase and costs decrease in the upcoming quarters, the
perception by patients of quality of life outcomes, and all other
statements in this release, other than historical facts, are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 ("PSLRA"). This statement
is included for the express purpose of availing IsoRay, Inc. of the
protections of the safe harbor provisions of the PSLRA. It is
important to note that actual results and ultimate corporate
actions could differ materially from those in such forward-looking
statements based on such factors as an audit of our financial
results which may change our preliminary numbers, physician
acceptance, training and use of our products, our ability to
successfully manufacture, market and sell our products, our ability
to manufacture our products in sufficient quantities to meet demand
within required delivery time periods while meeting our quality
control standards, our ability to enforce our intellectual property
rights, whether additional studies are released and support the
conclusions of past studies, whether ongoing patient quality of
life results with our products are favorable and in line with the
conclusions of clinical studies and initial patient results,
patient results achieved when our products are used for the
treatment of cancers and malignant diseases whether or not used in
conjunction with other treatments, successful completion of future
research and development activities, whether we, our distributors
and our customers will successfully obtain and maintain all
required regulatory approvals and licenses to market, sell and use
our products in its various forms, continued compliance with ISO
standards as audited by BSI, the success of our sales and marketing
efforts, the procedures and regulatory requirements mandated by the
FDA for 510(k) approval, changes in laws and regulations applicable
to our products, the scheduling of physicians who either delay or
do not schedule patients in the periods anticipated, the use of
competitors' products, less favorable reimbursement rates, and
other risks detailed from time to time in IsoRay's reports filed
with the SEC. Unless required to do so by law, we undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/isoray-announces-participation-at-the-19th-annual-rodman--renshaw-global-investment-conference-in-new-york-city-september-10-12-2017-300512047.html
SOURCE IsoRay, Inc.